Adenosine A 2A analogue reduces long-term neurologic injury after blunt spinal trauma

Journal of Surgical Research

Volumn 121, Issue 1, 2004, Pages 130-134

  Brett Reece, T ^a,c   Davis, Jonathan D ^a   Okonkwo, David O ^a   Maxey, Thomas S ^a   Ellman, Peter I ^a   Li, Xinning ^a   Linden, Joel ^a,b   Tribble, Curtis G ^a   Kron, Irving L ^a   Kern, John A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

A 2A receptor; adenosine; apoptosis; hemodynamics; inflammation; motor function; rabbit; spinal cord injury; trauma

Indexed keywords

ADENOSINE A2A RECEPTOR AGONIST; ATL 146 E; SODIUM CHLORIDE; UNCLASSIFIED DRUG; 4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; ADENOSINE A2A RECEPTOR; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; PURINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; ETHICS; HEMODYNAMICS; HINDLIMB; MIDGUT; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; RABBIT; SPINE INJURY; TREATMENT OUTCOME; ANIMAL; BLUNT TRAUMA; DRUG POTENTIATION; PHYSIOLOGY; SPINAL CORD INJURY;

ANIMALS; CYCLOHEXANECARBOXYLIC ACIDS; PURINES; RABBITS; RECEPTOR, ADENOSINE A2A; SPINAL CORD INJURIES; WOUNDS, NONPENETRATING;

EID: 4444321572     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2004.04.006     Document Type: Article

References (20)

1. M.B. Bracken, D.H. Freeman Jr, K. Hellenbrand Incidence of acute traumatic hospitalized spinal cord injury in the United States, 19701977 Am. J. Epidemiol 113 1981 615
2. M.B. Bracken, M.J. Shepard, W.F. Collins A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study N. Engl. J. Med 322 1990 1405
3. M.B. Bracken, M.J. Shepard, T.R. Holford Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study JAMA 277 1997 1597
4. M.B. Bracken, W.F. Collins, D.F. Freeman Efficacy of methylprednisolone in acute spinal cord injury JAMA 251 1984 45
5. E.R. George, D.J. Scholten, C.M. Buechler Failure of methylprednisolone to improve the outcome of spinal cord injuries Am. Surg 61 1995 659
6. V. Pointillart, M.E. Petitjean, L. Wiart Pharmacological therapy of spinal cord injury during the acute phase Spinal Cord 38 2000 71
7. T. Matsumoto, T. Tamaki, M. Kawakami Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury Spine 26 2001 426
8. J. Vinten-Johansen, V.H. Thourani, R.S. Ronson Broad-spectrum cardioprotection with adenosine Ann. Thorac. Surg 68 1999 1942
9. D.C. Cassada, C.G. Tribble, S.M. Long Adenosine A2A analogue ATL-146e reduces systemic tumor necrosing factor-alpha and spinal cord capillary platelet-endothelial cell adhesion molecule-1 expression after spinal cord ischemia J. Vasc. Surg 35 2002 994
10. J. Vinten-Johansen, Z.Q. Zhao, J.S. Corvera Adenosine in myocardial protection in on-pump and off-pump cardiac surgery Ann. Thorac. Surg 75 2003 S691
11. D.C. Cassada, C.G. Tribble, J.S. Young Adenosine A2A analogue improves neurologic outcome after spinal cord trauma in the rabbit J. Trauma 53 2002 225
12. S.J. Gerndt, J.L. Rodriguez, J.W. Pawlik Consequences of high-dose steroid therapy for acute spinal cord injury J. Trauma 42 1997 279
13. K.A. Gerhart, R.L. Johnson, J. Menconi Utilization and effectiveness of methylprednisolone in a population-based sample of spinal cord injured persons Paraplegia 33 1995 316
14. J. Linden Molecular approach to adenosine receptors receptor-mediated mechanisms of tissue protection Annu. Rev. Pharmacol. Toxicol 41 2001 775
15. G.W. Sullivan, D.D. Lee, W.G. Ross Activation of A2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils J. Leukocyte Biol 75 2004 127
16. G.W. Sullivan, J.M. Rieger, W.M. Scheld Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists Br. J. Pharmacol 132 2001 1017
17. G.W. Sullivan, J. Linden, E.L. Hewlett Adenosine and related compounds counteract tumor necrosis factor-alpha inhibition of neutrophil migration Implication of a novel cyclic AMP-independent action on the cell surface J. Immunol 145 1990 1537
18. D.K. Glover, M. Ruiz, K. Takehana Pharmacological stress myocardial perfusion imaging with the potent and selective A(2A) adenosine receptor agonists ATL193 and ATL146e administered by either intravenous infusion or bolus injection Circulation 104 2001 1181
19. M.S. Fenster, M.D. Feldman, G. Camarano Correlation of adenosine thallium 201 perfusion patterns with markers for inducible ischemia Am. Heart J 133 1997 406
20. D.C. Cassada, C.G. Tribble, A.K. Kaza Adenosine analogue reduces spinal cord reperfusion injury in a time- dependent fashion Surgery 130 2001 230